198 related articles for article (PubMed ID: 17525004)
1. PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease.
Sharma R; Singh B; Mahajan M
Kaohsiung J Med Sci; 2007 May; 23(5):225-31. PubMed ID: 17525004
[TBL] [Abstract][Full Text] [Related]
2. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome.
Koubaa N; Nakbi A; Hammami S; Attia N; Mehri S; Ben Hamda K; Ben Farhat M; Miled A; Hammami M
Clin Biochem; 2009 Jun; 42(9):771-6. PubMed ID: 19269283
[TBL] [Abstract][Full Text] [Related]
3. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
Sarandol A; Sarandol E; Eker SS; Karaagac EU; Hizli BZ; Dirican M; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1103-8. PubMed ID: 16716479
[TBL] [Abstract][Full Text] [Related]
5. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk.
Mendonça MI; Dos Reis RP; Freitas AI; Pereira A; Sousa AC; Freitas S; Ornelas I; Freitas C; Brehm A; Araújo JJ
Rev Port Cardiol; 2010 Apr; 29(4):571-80. PubMed ID: 20734577
[TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
7. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
Quéméneur T; Martin-Nizard F; Kandoussi A; Kyndt X; Vanhille P; Hachulla E; Hatron PY; Fruchart JC; Duriez P; Lambert M
Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573
[TBL] [Abstract][Full Text] [Related]
8. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
[TBL] [Abstract][Full Text] [Related]
9. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus.
Singh S; Venketesh S; Verma JS; Verma M; Lellamma CO; Goel RC
Indian J Med Res; 2007 Jun; 125(6):783-7. PubMed ID: 17704557
[TBL] [Abstract][Full Text] [Related]
12. PON1 M/L55 mutation protects high-risk patients against coronary artery disease.
Oliveira SA; Mansur AP; Ribeiro CC; Ramires JA; Annichino-Bizzacchi JM
Int J Cardiol; 2004 Mar; 94(1):73-7. PubMed ID: 14996478
[TBL] [Abstract][Full Text] [Related]
13. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?
Dursun P; Demirtaş E; Bayrak A; Yarali H
Hum Reprod; 2006 Jan; 21(1):104-8. PubMed ID: 16155079
[TBL] [Abstract][Full Text] [Related]
14. LDL molecular size as risk factor in coronary artery disease.
Kozma L; Fodor J; Chockalingam A; Sussex B
Acta Med Hung; 1992-1993; 49(1-2):65-77. PubMed ID: 1296188
[TBL] [Abstract][Full Text] [Related]
15. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status.
Domagała TB; Łacinski M; Trzeciak WH; Mackness B; Mackness MI; Jakubowski H
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(5):4-10. PubMed ID: 17543199
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid and oxidizability of lipid and proteins and antioxidant status in patients with coronary artery disease.
Serdar Z; Yeşilbursa D; Dirican M; Sarandöl E; Serdar A
Cell Biochem Funct; 2007; 25(6):655-64. PubMed ID: 17006879
[TBL] [Abstract][Full Text] [Related]
17. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
18. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.
Atamer A; Kocyigit Y; Ecder SA; Selek S; Ilhan N; Ecder T; Atamer Y
J Nephrol; 2008; 21(6):924-30. PubMed ID: 19034878
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
[TBL] [Abstract][Full Text] [Related]
20. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
